Targets › YAP1
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.
Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis. (UniProt, P46937)
Open in Phaseline: the race on YAP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Medley Therapeutics | YAP101 (AAV9-Sav-shRNA) AAV9-delivered short hairpin RNA targeting YAP1 to promote cardiac regeneration | YAP1 | Phase 1 | Heart Failure With Reduced Ejection Fraction | Dec 2026 |
Heart Failure With Reduced Ejection Fraction (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.